KROS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KROS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Keros Therapeutics's Shareholder Yield % was -5.64%.
The historical data trend for Keros Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Shareholder Yield % | Get a 7-Day Free Trial | - | 0.01 | 0.01 | -18.79 | -0.82 |
Keros Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shareholder Yield % | Get a 7-Day Free Trial | -18.79 | -34.50 | -0.79 | -1.39 | -0.82 |
For the Biotechnology subindustry, Keros Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Shareholder Yield % falls into.
Keros Therapeutics's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:
Shareholder Yield % | = | Dividend Yield % | + | Buyback Yield % | + | Net Debt Paydown Yield % |
= | 0 % | + | 0 % | + | -0.82 % | |
= | -0.82 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Keros Therapeutics (NAS:KROS) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Thank you for viewing the detailed overview of Keros Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith Regnante | officer: Chief Financial Officer | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Jennifer Lachey | officer: Chief Scientific Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Christopher Rovaldi | officer: Chief Operating Officer | C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139 |
Julius Knowles | director | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Simon Peter Cooper | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421 |
Claudia Ordonez | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Tomer Kariv | director, 10 percent owner | C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Ran Nussbaum | director, 10 percent owner | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jasbir Seehra | director, officer: Chief Executive Officer | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Arkin Bio Ventures Limited Partnership | 10 percent owner | 6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406 |
From GuruFocus
By Marketwired • 09-05-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By sperokesalga sperokesalga • 06-12-2023
By Marketwired • 08-07-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 07-03-2022
By Stock market mentor Stock market mentor • 02-07-2023
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 11-06-2023
By sperokesalga sperokesalga • 04-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.